GleamWall
中文EN

KRRO Korro Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1703647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.5%
TTM net income YoY-20.0%
TTM EPS YoY5.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,467.3%
Net margin-8,214.5%
FCF margin-4,943.8%
EBITDA margin-8,325.8%

Returns

ROE-113.3%
ROA-68.5%
ROIC (approx.)-140.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets40.3%
Debt / equity0.00x
Current ratio7.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-27.4%
Payout ratio—
Capex / revenue13.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$1.29M$1.09M$1.46M$2.55M$2.27M
R&D expense$12.10M$13.59M$12.95M$10.98M$13.82M$20.14M$19.74M$16.96M
SG&A expense$6.35M$6.52M$7.49M$6.19M$6.51M$7.29M$7.83M$8.35M
Operating income-$18.46M-$20.11M-$20.44M-$50.40M-$19.24M-$27.20M-$25.02M-$23.04M
Pretax income-$17.29M-$18.81M-$19.53M-$49.41M-$18.06M-$25.77M-$23.39M-$21.10M
Income tax$260,000$108,000$95,000$636,000$0$1,000$0$103,000
Net income-$17.55M-$18.92M-$19.62M-$50.04M-$18.06M-$25.77M-$23.39M-$21.20M
EBITDA-$18.06M-$19.71M-$20.06M-$49.75M-$18.04M-$26.00M-$23.80M-$21.79M
EPS (basic)-0.98-1.07-1.69—-1.92-2.74-2.49—
EPS (diluted)-0.98-1.07-1.69—-1.92-2.74-2.49—
Weighted avg. shares (diluted)17.87M17.62M11.60M—9.39M9.39M9.38M—
Balance sheet
Cash & equivalents$40.22M$24.91M$61.70M$21.82M$24.16M$33.61M$64.14M$55.64M
Short-term investments$64.78M$90.13M$52.27M$53.33M$68.32M$62.75M$50.81M$70.45M
Current assets$108.94M$120.63M$120.16M$82.37M$98.23M$102.63M$121.23M$131.53M
PP&E, net$7.24M$7.48M$7.80M$8.16M$24.40M$25.39M$26.68M$27.71M
Total assets$148.12M$163.45M$183.62M$113.51M$161.55M$180.43M$202.21M$226.24M
Current liabilities$14.92M$12.63M$14.79M$11.94M$14.64M$17.17M$12.88M$14.96M
Total liabilities$59.75M$60.22M$63.99M$62.07M$62.52M$65.32M$63.25M$65.83M
Shareholders' equity$88.37M$103.23M$119.63M$51.44M$99.03M$115.10M$138.96M$160.41M
Shares outstanding13.73M14.71M14.42M9.42M9.40M9.39M9.39M9.38M
Cash flow statement
Operating cash flow-$12.94M-$16.99M-$16.07M-$17.70M-$17.18M-$19.23M-$24.45M-$7.50M
Capital expenditure$27,000$37,000$21,000$84,000$175,000$140,000$119,000$1.45M
Free cash flow-$12.96M-$17.03M-$16.09M-$17.79M-$17.35M-$19.37M-$24.57M-$8.95M
Investing cash flow$28.26M-$17.90M-$32.24M$14.92M$7.60M-$11.30M$32.78M-$2.77M
Financing cash flow$0-$2.92M$88.21M$380,000$128,000$5,000$172,000$932,000
Depreciation & amortization$400,000$400,000$380,000$649,000$1.20M$1.20M$1.23M$1.25M
Stock-based compensation$2.81M$2.70M$2.73M$2.07M$1.82M$2.00M$1.76M$1.36M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.